

Nucleotide Ligands for Purinergic and Pyrimidinergetic Receptors (P2X and P2Y)

sorted by nucleotide analog

| Nucleotides | Cat. No. | Receptor type |
|-------------------------------------|----------|---|
| ATP | | |
| ATP | NU-1010 | P2Y ₁ , P2Y ₂ , P2Y ₄ , hP2Y ₆ , P2Y ₁₁ , P2X ₁₋₇ |
| NPE-caged ATP | NU-301 | release technology: P2Y ₁ , P2Y ₂ , P2Y ₄ , hP2Y ₆ , P2Y ₁₁ , P2X ₁₋₇ |
| DMB-caged ATP | NU-309 | release technology: P2Y ₁ , P2Y ₂ , P2Y ₄ , hP2Y ₆ , P2Y ₁₁ , P2X ₁₋₇ |
| ATP-γS | NU-406 | P2Y ₂ , P2Y ₁₂ ; enzymatic stable |
| ATP-αS | NU-408 | P2 ₁₁ ; enzymatic stable |
| ApCpp | NU-421 | P2 - purinoreceptor |
| AppCp | NU-422 | P2X - purinoreceptor |
| AppNHp | NU-407 | P2Y ₂ |
| NPE-caged AppNHp | NU-305 | P2Y ₂ ; release technology |
| Mant-AppNHp | NU-214 | P2Y ₂ ; release technology |
| 8-[(6-Amino)hexyl]-amino-ATP | NU-807 | P2Y |
| 8-Bromo-ATP | NU-114 | P2Y ₂ , P2X |
| Etheno-ATP | NU-1103 | P2Y |
| N⁶-Methyl-ATP | NU-1101 | P2Y, P2X ₂ |
| AP₄U | NU-528 | P2Y ₂ , P2Y ₄ , P2X ₁ |
| TNP-ATP | NU-221 | P2X ₁₋₄ , P2X |
| BzBzATP | NU-1620 | P2X ₇ |
| ADP | | |
| ADP | NU-1198 | P2Y ₁ , hP2Y ₆ , P2Y ₁₂ , P2Y ₁₃ |
| GTP | | |
| GTP-γS | NU-412 | P2Y ₁₂ , P2Y ₁₃ |
| CTP | | |
| CTP | NU-1011 | P2X ₃ , P2Y ₆ |
| UTP | | |
| UTP | NU-1013 | P2X ₁ , P2Y ₂ |
| 2-Thio-UTP | NU-1151 | P2Y ₂ , P2Y ₄ , P2Y ₆ |
| 4-Thio-UTP | NU-1156 | P2Y ₂ , P2Y ₄ |
| 5-Bromo-UTP | NU-121 | P2Y ₂ , P2Y ₄ |
| UTP-γS | NU-416 | P2Y ₂ , P2Y ₄ ; enzymatically stable |
| AP₄U | NU-528 | P2Y ₂ , P2Y ₄ , P2X ₁ |
| UDP | | |
| UDP | NU-1206 | Agonist: hP2Y ₆ ; competitive antagonist: P2Y ₁₄ |
| 3-Phenacyl-UDP | NU-1183 | Agonist: P2Y ₆ , P2Y ₂ , P2Y ₄ |
| 5-Iodo-UDP | NU-867 | Agonist: P2Y ₆ |
| UDPβS | NU-442 | P2Y ₆ |
| ITP | | |
| ITP | NU-1203 | P2Y ₂ , P2Y ₄ |
| Dinucleotides | | |
| AP₃A | NU-506 | P2Y ₁ , P2Y ₁₂ , P2Y ₁₃ , P2X ₁₋₄ |
| AP₄A | NU-507 | P2Y ₁ , P2Y ₂ , P2Y ₁₁ |
| AP₅A | NU-508 | P2Y _{1,2,4,12} , P2X ₁ , vascular P2X receptors |